Skip to contentE
Exousia Bio, Inc.
E
LMMYExousia Bio, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.75K$3.75Kderived— vs Q4 2023 Net Income-$5.25K-$5.25KderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Exousia Bio, Inc. · CIK 1939937 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$5,917— Operating Cash Flowderived-$1,414N/M Margins · derivedGross margin-157.8%
Net margin-140.1%
ended May 31, 2024 · filed Aug 30, 2024 · 91 d after period end